Trial Profile
Real world survey of Edoxaban for non-valvular atrial fibrillation patients using a Japanese healthcare database.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Apr 2019
Price :
$35
*
At a glance
- Drugs Edoxaban (Primary) ; Warfarin
- Indications Embolism; Stroke
- Focus Adverse reactions; Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 29 Mar 2019 Status changed from active, no longer recruiting to completed.
- 11 Jan 2018 New trial record